Insight Molecular Diagnostics announces attendance at two industry conferences

Insight Molecular Diagnostics (IMDX) announced attendance at two key industry conferences where it will discuss its GraftAssur technology, including its clinical kitted test under development. “Kidney transplant management is changing. Emerging medications such as anti-CD38 therapies have a chance at treating transplant rejection, and in-house testing will bring care where it belongs – closer to the patient,” said iMDx CEO Josh Riggs. “Our presentations this fall in both Singapore and Orlando highlight the bright potential of our technology and the strong global interest in our assay.”